[ASC-media] Media Alert: Innovative Technology to fast track Stem Cell Therapy in Australia - Stem Cell Workshop in Sydney Friday

Daniella Goldberg (Gene Genie Media) daniella at genegeniemedia.com.au
Tue Nov 26 16:25:05 PST 2013

When will patients benefit from stem cell therapy in Australia?
- The challenges of taking stem cells from the lab to the clinic -
SYDNEY, AUSTRALIA, Tuesday 26 November 2013 ­ Australian stem cell experts
are joining forces to address the future of stem cell research in Australia
and the critical gap in taking innovative stem cell therapies from the
laboratory to patients in the clinic.

Over 100 clinicians, scientists, policy makers, investors, IP lawyers,
patient advocates, pharma and biotech executives are participating in the
Workshop - Innovating the Marketplace with Stem Cells - hosted by the NSW
Stem Cell Network to take a serious look at this vital issue facing
Australia¹s stem cell industry.
Professor Bernie Tuch, Founder and Director of the NSW Stem Cell Network
said that Australia is the birth place of innovative ideas in stem cell
research and therapies and has demonstrated commercial success as the
birthplace of the world¹s biggest stem cell company, Mesoblast (ASX:MSB) and
world leading IVF clinic Genea. Clinically we also have some of the most
innovative research including success in clinical trials for stem cell
treatment of a corneal eye disease at University of NSW and for treatment
resistant Crohn¹s disease at the University of Western Australia.
In light of these successes, the Australian industry is plagued by a loss of
our IP, talent and manufacture to countries abroad, that are better
supported with commercialisation and investment opportunities.
ŒA collective effort is needed to push this industry forward. Basic
researchers need to become educated as to the part they play in getting
their technology to patients and interactions need to improve between
Australia¹s researchers, clinicians, commercial and regulatory bodies
towards driving realistic solutions.¹
ŒThe US, Switzerland, Germany, the UK, many countries are currently running
clinical trials for which we have the expertise in Australia, many even
utilise Australian technologies. We cannot miss the chance to lead this
industry by sitting back and waiting¹, said Professor Tuch.
Key-note speaker, Professor Igor Slukvin, University Wisconsin-Madison will
be presenting a new stem cell technology, CymerusTM, which has the potential
to manufacture billions of human Mesenchymal stem cells from a single
embryonic stem cell and poses great therapeutic for patients.
Dr Slukvin invented his technology in Wisconsin laboratory alongside
Professor James Thomson, who is well-known for creating the world¹s first
embryonic stem (ES) cell line in 1998 and human induced pluripotent stem
cells in 2007.  
³Stem cell therapy has not taken the path that scientists predicted over ten
years ago. We have found only one type of stem cell, The  Mesenchymal stem
cell show great promise and is ready for clinical trial for a broad range of
diseases right now,² says Dr Slukvin.
Mesenchymal stem cells works by stimulating the body¹s own healing systems
and have the potential to remedy a broad range of diseases including
cardiovascular disease, diabetes, diseases of the blood, lung, kidney, eyes
teeth and immune system diseases.
Dr Paul Brock who has Motor Neurone Disease and is a long time advocate of
stem cell technologies in Australia says, ³I have been disappointed at what
has appeared to me to have been the slow take up of Australian research
projects utilising the legislative green light given to embryonic stem cell
research and somatic cell nuclear transfer research by those Bills.²
However he is Œconfident that effectively resourced, internationally
collaborative stem cell research, thriving within a multidisciplinary
cross-siloed scientific approach to ultimately producing successful
therapeutic outcomes, will play a vital role in better understanding the
causes of and eventually developing cures for currently incurable, terminal
neurological diseases such as Motor Neurone Disease¹
Recent activity in Australian stem cell research and industry indicates that
if properly supported this slow up take is about to change.
RSVP: Daniella Goldberg PhD, Gene Genie Media: Tel: 0416 211 067 eml:
Daniella at genegeniemedia.com.au

Event:  Stem Cell Workshop ­ Innovating the Marketplace with Stem Cells

Time: 830am  - 7pm
Date: Friday 29 November
Venue: Convention Centre, Darling Harbour, Sydney
Stem Cell Workshop Program and registration:


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131127/29c6ed88/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: 7880150B-E893-4A62-A31A-C62CFCC5E3D4.png
Type: image/png
Size: 50036 bytes
Desc: not available
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131127/29c6ed88/attachment-0001.png>

More information about the ASC-media mailing list